Inflammatory Cytokine Levels After Endovascular Therapy in Patients With Peripheral Artery Disease

Angiology ◽  
2016 ◽  
Vol 68 (8) ◽  
pp. 734-740 ◽  
Author(s):  
Yasushi Ueki ◽  
Takashi Miura ◽  
Yusuke Miyashita ◽  
Souichiro Ebisawa ◽  
Hirohiko Motoki ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Endovascular Therapy ◽  
Inflammatory Cytokine ◽  
Enzyme Linked Immunosorbent Assay ◽  
Peripheral Artery ◽  
Stent Restenosis ◽  
Tnf Α ◽  
Cytokine Levels ◽  
Artery Disease ◽  
In Stent Restenosis

We evaluated the impact of endovascular therapy (EVT) on inflammatory cytokine levels and its relationship with in-stent restenosis in patients with peripheral artery disease. The study prospectively enrolled 35 patients with intermittent claudication who underwent EVT of the iliofemoral artery. Levels of interleukin 6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor α (TNF-α) were measured using enzyme-linked immunosorbent assay before and at 2 hours, 4 hours, and 3 months after EVT. All cytokine levels increased significantly after EVT (IL-6 [pg/mL]: from 1.51 [0.84-1.93] before EVT to 6.97 [4.05-20.41] at 2 hours and 13.29 [4.57-31.88] at 4 hours; MCP-1 [pg/mL]: from 326.65 [265.60-406.55] before EVT to 411.18 [341.21-566.27] at 2 hours and 519.36 [383.58-644.85] at 4 hours; TNF-α [pg/mL]: from 1.08 [0.77-1.29] before EVT to 1.25 [0.94-1.81] at 2 hours and 1.27 [0.95-1.59] at 4 hours, all P < .001). However, cytokine levels did not differ significantly between lesions with and without in-stent restenosis. Overall, our results suggest that EVT significantly increases IL-6, MCP-1, and TNF-α levels in the ischemic leg, but this effect is not associated with a higher rate of in-stent restenosis.

scholarly journals Reply: Inflammatory Cytokine Levels After Endovascular Therapy in Patients With Peripheral Artery Disease

Angiology ◽  
2017 ◽  
Vol 68 (8) ◽  
pp. 742-742
Author(s):  
Yasushi Ueki ◽  
Takashi Miura ◽  
Yusuke Miyashita ◽  
Souichiro Ebisawa ◽  
Hirohiko Motoki ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Endovascular Therapy ◽  
Inflammatory Cytokine ◽  
Peripheral Artery ◽  
Cytokine Levels ◽  
Artery Disease

scholarly journals Histopathology of In-Stent Restenosis in Patients With Peripheral Artery Disease

Circulation ◽  
1997 ◽  
Vol 95 (8) ◽  
pp. 1998-2002 ◽  
Author(s):  
Marianne Kearney ◽  
Ann Pieczek ◽  
Laura Haley ◽  
Douglas W. Losordo ◽  
Vicente Andres ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Peripheral Artery ◽  
Stent Restenosis ◽  
Artery Disease ◽  
In Stent Restenosis

scholarly journals Peripheral stent technology and current status for endovascular treatment of femoropopliteal artery disease: a clinical review

2018 ◽  
Vol 6 (5) ◽  
pp. 1474
Author(s):  
Bhargav Dave ◽  
Rikin Shah
Keyword(s):  
Peripheral Artery Disease ◽  
Current Status ◽  
Stent Fracture ◽  
Peripheral Artery ◽  
Stent Restenosis ◽  
Nitinol Stents ◽  
Long Term Follow Up ◽  
Drug Eluting ◽  
Artery Disease ◽  
In Stent Restenosis

Over the past decade, the treatment of peripheral artery disease poses a number of technical challenges for the physician. The primary rationale of this article is to review the available literature on the current practices involved in the treatment of peripheral artery disease (PAD), particularly the femoropopliteal lesions. It is evident from the landmark clinical trials that the use of self-expanding drug-eluting stents (DES) has become the most favored clinical strategy for treating peripheral lesions above the knee. It is chiefly due to higher patency rates, and minimal in-stent restenosis and stent fracture rates associated with the use of DES. The technical evolution in the endovascular approach from the use of bare nitinol stents to DES for treating PAD and the factors responsible for this transformation have also been reviewed with their respective justification. Presently there is a need of DES technology for the treatment of femoropopliteal lesions, which can reduce the risk of stent fracture and in-stent restenosis for longer lesions while maintaining patency during long-term follow-up. To conclude, this review establishes that self-expanding DES and drug coated balloons using anti-proliferative drugs like sirolimus and paclitaxel are currently the most effective method of treating the femoropopliteal lesions in PAD.

scholarly journals MiR-140-3p is Involved in In-Stent Restenosis by Targeting C-Myb and BCL-2 in Peripheral Artery Disease

2018 ◽  
Vol 25 (11) ◽  
pp. 1168-1181 ◽  
Author(s):  
Zheng-Rong Zhu ◽  
Qiong He ◽  
Wei-Bin Wu ◽  
Guang-Qi Chang ◽  
Chen Yao ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Peripheral Artery ◽  
Stent Restenosis ◽  
Artery Disease ◽  
In Stent Restenosis

scholarly journals Angiogenin—A Proposed Biomarker for Cardiovascular Disease—Is Not Associated With Long-Term Survival in Patients With Peripheral Artery Disease

Angiology ◽  
2021 ◽  
pp. 000331972110043
Author(s):  
Clemens Höbaus ◽  
Gerfried Pesau ◽  
Bernhard Zierfuss ◽  
Renate Koppensteiner ◽  
Gerit-Holger Schernthaner
Keyword(s):  
Peripheral Artery Disease ◽  
Cox Regression ◽  
Ankle Brachial Index ◽  
Limb Ischemia ◽  
Cross Sectional Study ◽  
Enzyme Linked Immunosorbent Assay ◽  
Peripheral Artery ◽  
Cross Sectional ◽  
Term Survival ◽  
Artery Disease

We evaluated angiogenin as a prospective biomarker in peripheral artery disease (PAD) patients with and without claudication symptoms. A pilot study suggested an elevation of angiogenin in critical limb ischemia. However, in PAD patients, the predictive value of angiogenin has not yet been evaluated. For this purpose, 342 patients with PAD (age: 69 ± 10 years, 34.5% women) were followed-up for 7 years in a cross-sectional study. Angiogenin was measured by enzyme-linked immunosorbent assay. All-cause and cardiovascular mortality were analyzed by Cox regression. Angiogenin levels were higher in men ( P = .001) and were associated with patient waist-to-hip ratio ( P < .001), fasting triglycerides ( P = .011), and inversely with estimated glomerular filtration rate ( P = .009). However, angiogenin showed no association with age, characteristics of diabetes, markers of lipid metabolism, or C-reactive protein. Angiogenin did not correlate with markers of angiogenesis such as vascular endothelial growth factor, angiopoietin-2, or tie-2. Furthermore, angiogenin was not associated with PAD Fontaine stages or with patient ankle-brachial index in addition to all-cause mortality (hazard ratio [HR] = 1.09 [95% CI: 0.89-1.34]) or cardiovascular morality (HR = 1.05 [0.82-1.35]). These results suggest that angiogenin does not provide further information regarding outcome prediction in patients with PAD.

scholarly journals Impact of Objective Malnutrition Status on the Clinical Outcomes in Patients With Peripheral Artery Disease Following Endovascular Therapy

2018 ◽  
Vol 82 (3) ◽  
pp. 847-856 ◽  
Author(s):  
Miyuki Yokoyama ◽  
Tetsu Watanabe ◽  
Yoichiro Otaki ◽  
Ken Watanabe ◽  
Taku Toshima ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Peripheral Artery Disease ◽  
Endovascular Therapy ◽  
Peripheral Artery ◽  
Artery Disease
Sign in / Sign up

Export Citation Format

Share Document